Show simple item record

dc.contributor.authorBurza, Sakib
dc.contributor.authorSinha, Prabhat K
dc.contributor.authorMahajan, Raman
dc.contributor.authorLima, María Angeles
dc.contributor.authorMitra, Gaurab
dc.contributor.authorVerma, Neena
dc.contributor.authorBalasegarem, Manica
dc.contributor.authorDas, Pradeep
dc.date.accessioned2014-01-20T21:27:02Z
dc.date.available2014-01-20T21:27:02Z
dc.date.issued2014-01
dc.identifier.citationFive-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India. 2014, 8 (1):e2603 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735
dc.identifier.pmid24392168
dc.identifier.doi10.1371/journal.pntd.0002603
dc.identifier.urihttp://hdl.handle.net/10144/311611
dc.description.abstractVisceral Leishmaniasis (VL; also known as Kala-azar) is an ultimately fatal disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL treated with 20 mg/Kg intravenous liposomal amphotericin B (Ambisome) demonstrated a 98% cure rate at 6-months. Between July 2007 and August 2012, Médecins Sans Frontières (MSF) and the Rajendra Memorial Research Institute (RMRI) implemented a VL treatment project in Bihar, India-an area highly endemic for Leishmania donovani-using this regimen as first-line treatment.
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen_GB
dc.subjectKala Azar/Visceral Leishmaniasisen_GB
dc.titleFive-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, Indiaen
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB
refterms.dateFOA2019-03-04T10:58:28Z
html.description.abstractVisceral Leishmaniasis (VL; also known as Kala-azar) is an ultimately fatal disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL treated with 20 mg/Kg intravenous liposomal amphotericin B (Ambisome) demonstrated a 98% cure rate at 6-months. Between July 2007 and August 2012, Médecins Sans Frontières (MSF) and the Rajendra Memorial Research Institute (RMRI) implemented a VL treatment project in Bihar, India-an area highly endemic for Leishmania donovani-using this regimen as first-line treatment.


Files in this item

Thumbnail
Name:
Burza et al-2014-Five year field ...
Size:
698.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record